SCHEMBL2483169

SCHEMBL2483169

CC(C)Nc1ccc(N)nc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.45
NOS2 P35228 1/20 0.45
TDP1 Q9NUW8 2/20 0.41
HSD17B10 Q99714 2/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
CYP3A4 P08684 1/20 0.41
THRB P10828 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
ALOX12 P18054 1/20 0.41
RECQL P46063 1/20 0.41
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
SYK P43405 1/20 0.37
KCNH3 Q9ULD8 2/20 0.37
ALPL P05186 1/20 0.36
KDM4E B2RXH2 2/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19079767 0.78 HDAC1 (0.39) NOS3NOS2ALDH1A1ALPLKDM4E
SCHEMBL2790633 0.77 HCAR3 (0.43) NOS3NOS2TDP1HSD17B10ALDH1A1
SCHEMBL12697206 0.77 TDP1 (0.43) TDP1HSD17B10ALDH1A1LMNACYP3A4
SCHEMBL1746354 0.76
SCHEMBL12695030 0.75 TDP1 (0.41) TDP1HSD17B10ALDH1A1LMNACYP3A4
SCHEMBL3824428 0.75 KCNQ3 (0.42) TDP1HSD17B10ALDH1A1LMNACYP3A4
SCHEMBL12380190 0.75 KCNH3 (0.44) TDP1HSD17B10ALDH1A1LMNACYP3A4
SCHEMBL13838566 0.75 ABL1 (0.43) SYKPIK3CDCDK8
SCHEMBL22175094 0.74 MAPT (0.38) NOS3NOS2ALPLCPB2KIT
SCHEMBL1255075 0.73 PIK3CD (0.47) NOS3NOS2ALDH1A1CYP3A4ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013083666-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE F. HOFFMANN-LA ROCHE AG (CH) 2013-06-13 WO disclosed
EP-2225245-B1 N-phenyl-imidazo(1,2-a)pyridine-2-carboxamide compounds, preparation thereof and therapeutic application thereof SANOFI SA (FR) 2011-10-19 EP disclosed
US-20100317620-A1 N-PHENYLIMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE COMPOUNDS, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-12-16 US disclosed
CN-101910175-A N-phenylimidazo [1,2-a ] pyridine-2-carboxamide compounds, preparation and therapeutic use thereof SANOFI AVENTIS 2010-12-08 CN disclosed
EP-2225245-A2 N-PHENYL-IMIDAZOÝ1,2-A¨PYRIDINE-2-CARBOXAMIDE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF Sanofi-Aventis (FR) 2010-09-08 EP disclosed
WO-2009115651-A2 N-PHENYL-IMIDAZO[1,2-A]PYRIDINE-2-CARBOXAMIDE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317620-A1 N-PHENYLIMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE COMPOUNDS, PREPARATION AND THERAPEUTIC USE THEREOF GLS, REN, XDH NOS3 1794/4885NOS2 1310/4885TDP1 1810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.